Publication at First Faculty of Medicine |
2022
Abstract
Molecularly targeted therapy and increasingly immunotherapy have a firm place in the treatment algorithm of oncological care across almost all diagnoses. Kidney cancer is one of the first diagnoses where both modalities have gained in high importance.
In bladder cancer, after many years of local immunotherapy, systemic immunotherapy has become anchored in the indication tables as well, and recently the door to targeted treatment has also been opened. The review article summarizes the current state and possibilities of using immunotherapy and molecularly targeted treatment in kidney and bladder cancers.